NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, reported results for the fiscal year-ended October 31, 2010. Gross revenues for the fiscal year ended October 31, 2010 increased to $508,500 as compared with a minimal amount for the corresponding period in 2009. This increase was largely due to revenue from a Federal grant as well as the sale of prior years’ Net Operating Losses through a New Jersey Economic Development Authority program.
